Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR) - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, presented new clinical data from the Company’s Phase 1b/2a clinical trial of the orally administered combination of nanatinostat (Nstat) in combination with the antiviral valganciclovir for the treatment of EBV-associated relapsed/refractory lymphomas. Read More

Viracta Therapeutics to Present at the Evercore ISI HealthCONx Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 2:45 pm ET in Boston, MA. Read More

Viracta Receives Fast Track Designation for Nanatinostat Combination for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies. Read More

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, will present new clinical data from the Company’s Phase 1b/2a clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of EBV-associated lymphomas during an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida. Read More

Events

December 4, 2019

Evercore ISI HealthCONx Conference, Boston, MA Read More

December 7-10, 2019

61st ASH Annual Meeting & Exposition at the Orange County Convention Center (OCCC), Orlando, FL Read More

October 18, 2019

5th Annual Solebury Trout Private Company Showcase, Oct. 18, 2019 In NY Read More

Recent News

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR) - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, presented new clinical data from the Company’s Phase 1b/2a clinical trial of the orally administered combination of nanatinostat (Nstat) in combination with the antiviral valganciclovir for the treatment of EBV-associated relapsed/refractory lymphomas. Read More

Viracta Therapeutics to Present at the Evercore ISI HealthCONx Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 2:45 pm ET in Boston, MA. Read More

Viracta Receives Fast Track Designation for Nanatinostat Combination for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies. Read More

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr. Pierluigi Porcu of the Sidney Kimmel Cancer Center, Thomas Jefferson University, will present new clinical data from the Company’s Phase 1b/2a clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of EBV-associated lymphomas during an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida. Read More | PDF

Events

December 4, 2019

Evercore ISI HealthCONx Conference, Boston, MA Read More

December 7-10, 2019

61st ASH Annual Meeting & Exposition at the Orange County Convention Center (OCCC), Orlando, FL Read More

October 18, 2019

5th Annual Solebury Trout Private Company Showcase, Oct. 18, 2019 In NY Read More